Appendix 4D and Half Year Financial Report
Filed with ASX · · 27 pages · English
Summary by 6ix AI
The report indicates a significant increase in the loss from ordinary activities after tax, attributed to the owners of Invion Ltd. No dividends were declared or paid during this financial period, reflecting the company's focus on managing its financial position. The report also highlights key operational milestones, including advancements in the Photosoft technology and collaborations for funding and development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Invion
- Appendix 4C and Quarterly Activities Report - December 2025
- Major Shareholders Lead Invion $1.3M Capital Raise
- Trading Halt
- Pause in Trading
- Hanlim & Korean Government Fund Pathway to Clinical Trial
Later from Invion
- Skin Cancer Trial Moves to BCC With More Encouraging Signals
- Appendix 4C and Quarterly Activities Report - March 2026
- Photosoft Platform Expands to Eye Diseases Via Partnership
- Appendix 4C and Quarterly Activities Report - June 2026
- IVX Credentialed International Biotech Leader Joins Board
Follow Invion into a list and get an email when it puts out news.
Follow Invion